about
Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled studyInhibition of microRNA function by antimiR oligonucleotidesElucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry dataPolychromatic flow cytometry in evaluating rheumatic disease patientsLupus nephritis: the evolving role of novel therapeuticsArtesunate abolishes germinal center B cells and inhibits autoimmune arthritisThe phosphatase JKAP/DUSP22 inhibits T-cell receptor signalling and autoimmunity by inactivating LckEfficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre studyThe MRL/lpr mouse strain as a model for neuropsychiatric systemic lupus erythematosus.Defective regulatory B-cell compartment in patients with immune thrombocytopeniaImmune dysregulation in immune thrombocytopenia.Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosusPersonalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus PatientsSystemic lupus erythematosus: Extent and patterns of off-label use of rituximab for SLE.Rationale for B cell targeting in SLENon-infectious pulmonary toxicity of rituximab: a systematic review.Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation.Primary Sjögren's syndrome is characterized by distinct phenotypic and transcriptional profiles of IgD+ unswitched memory B cellsDefective expression and function of the leukocyte associated Ig-like receptor 1 in B lymphocytes from systemic lupus erythematosus patients.SM934 treated lupus-prone NZB × NZW F1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development.Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice.Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A.Murine models of systemic lupus erythematosusNovel therapeutic agents in clinical development for systemic lupus erythematosus.Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.A CD8 T cell/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus.In-/off-label use of biologic therapy in systemic lupus erythematosus.Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infectionPreventing autoimmunity protects against the development of hypertension and renal injury.Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model.B-cell subsets in the joint compartments of seropositive and seronegative rheumatoid arthritis (RA) and No-RA arthritides express memory markers and ZAP70 and characterize the aggregate pattern irrespectively of the autoantibody status.Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedsideInhibition of B lymphocyte-induced maturation protein-1 reduces the production of autoantibody and alleviates symptoms of systemic lupus erythematosusSafety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).A small CD11b(+) human B1 cell subpopulation stimulates T cells and is expanded in lupusSilencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus miceDiversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus.Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation.The genetics of lupus: a functional perspective.Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.
P2860
Q21089923-1E125352-78E3-4AD9-95D6-6BD37D8CD6A6Q21198757-166CC938-7978-4576-A9AB-DDFD45C7D943Q24605194-41C91679-C601-440F-AEBA-98C0A08B95BCQ26827075-19D7D38E-F900-4E69-851A-77624C653A64Q26998390-7AD5B74C-1117-43FE-8128-07BF87D53947Q28541811-20E17F7B-945A-47E6-ADC4-16C3ACD87C42Q28591171-E18E9867-54EC-4B0F-889F-49B8182D369EQ28660706-2F66696A-EADB-46E0-A1F5-FBB472FF11DFQ30476952-A1E0892D-30CF-4F52-97E3-FA1E743E0318Q33402659-3643DE97-3CE2-4D12-845D-0AB6C8887A2EQ33407649-F3D533E5-9AE8-471D-B541-BFBFEED52412Q33577386-812CA61F-95AE-4B15-9051-0577667331BFQ33662822-037D5B6F-890B-445D-A339-75042F1980D4Q33811635-065CCD2A-82F6-44BA-BC2B-D7D18032DA9CQ33829700-DCD80F36-7B7D-4FBB-9C5D-D28F08A3AFB0Q34096300-CDCD5A91-A29A-49B2-A729-CF11C127DEE7Q34125054-265C283E-FF1A-497C-82B3-53D4D2B4CD92Q34159795-7D0611B3-80F1-4292-9CD8-D40305382833Q34166502-66571C6D-BE81-481E-92FE-84C95ED2F3E2Q34184574-0A215647-EA4F-41C2-A692-7B2BF6652CE6Q34278189-2A9F77C7-A9DC-4F1B-95DA-C41F4FA8A8D6Q34335192-67F2EF28-8C7C-437D-92BE-11B785D6BEA5Q34591019-5D271C0F-05C5-4089-9B43-DA8306A8C624Q34704902-A259959B-4735-4290-B9C6-6681EECA0D53Q34901832-6EB32892-8522-4DEA-9FB0-806D79C38C04Q35023185-E25D3E0F-EECC-4F9F-85D5-B3269254486BQ35094536-9251552D-6D01-4AD9-A9AE-441106224F47Q35102339-65D59084-90E4-48EE-AE49-333CB95E5B3BQ35159241-0AE79EAA-E810-4540-B554-761F5657FF64Q35170050-9CEDC505-0C29-4F6E-B1C7-62D4051CC1B4Q35286950-C10F6934-73FB-40CE-BDA5-BFC1975B503BQ35309470-36097D0F-5378-4659-A7B9-34E749284666Q35318479-7948F66F-2A57-444E-8DAA-29CD49B6E750Q35557832-88F5ACB3-91D5-4026-B789-9C47E875C042Q35627702-6468FCF6-2268-4ACD-BB41-CF2E2B107F70Q35673271-6C935265-C677-4313-A642-061EFEAC78C8Q35881985-6BBFD566-73C2-4297-B6C1-D075EAE36C07Q36118295-60312AD1-6718-4683-A464-BCCD56FC1AE7Q36245989-54A72498-4A65-4FFF-85F7-684DDC7B5252Q36278027-BF9D907F-0817-4BF4-92B2-FEF424AADC16
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
B cells as therapeutic targets in SLE.
@en
B cells as therapeutic targets in SLE.
@nl
type
label
B cells as therapeutic targets in SLE.
@en
B cells as therapeutic targets in SLE.
@nl
prefLabel
B cells as therapeutic targets in SLE.
@en
B cells as therapeutic targets in SLE.
@nl
P2860
P356
P1476
B cells as therapeutic targets in SLE.
@en
P2093
F Eun-Hyung Lee
Iñaki Sanz
P2860
P2888
P304
P356
10.1038/NRRHEUM.2010.68
P407
P577
2010-06-01T00:00:00Z